CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

CAT

914.62

+1.13%↑

322.19

-1.82%↓

GEV.US

930.4

-0.42%↓

RTX

178.55

-1.33%↓

215.74

+0.08%↑

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Închisă

1.25 -2.34

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.25

Maxim

1.3

Indicatori cheie
By Trading Economics
Venit	-1.5M -19M
Vânzări	1.7M 1.5M
EPS	-0.06
Marjă de profit	-1,250.946
Angajați	116
EBITDA	-987K -17M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+807.14% upside

Dividende
By Dow Jones
Următoarele câștiguri	31 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-162M 464M
Deschiderea anterioară	3.59
Închiderea anterioară	1.25

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 iun. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 iun. 2026, 15:41 UTC

Principalele dinamici ale pieței

American Battery Shares Jump on Energy Department Victory

8 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 iun. 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 iun. 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 iun. 2026, 21:57 UTC

Achiziții, Fuziuni, Preluări

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 iun. 2026, 21:56 UTC

Achiziții, Fuziuni, Preluări

Salesforce Agrees to Buy m3ter

8 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 iun. 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 iun. 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 iun. 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 iun. 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 iun. 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 iun. 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 iun. 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 iun. 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 iun. 2026, 16:55 UTC

Achiziții, Fuziuni, Preluări

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 iun. 2026, 16:54 UTC

Achiziții, Fuziuni, Preluări

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 iun. 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 iun. 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 iun. 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 iun. 2026, 16:03 UTC

Achiziții, Fuziuni, Preluări

Orange Bought Stake From Lorca

8 iun. 2026, 16:01 UTC

Achiziții, Fuziuni, Preluări

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 iun. 2026, 16:01 UTC

Achiziții, Fuziuni, Preluări

Orange Acquires 100% Ownership of MasOrange

8 iun. 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 iun. 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 iun. 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 iun. 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

807.14% sus

Prognoză pe 12 luni

Medie 11.43 USD 807.14%

Maxim 22 USD

Minim 7 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.